187 related articles for article (PubMed ID: 36314338)
21. Inetetamab in combination with rapamycin and chemotherapy for trastuzumab-treated metastatic human epidermal growth factor receptor 2-positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway.
Wang A; Li C; Jiang Q; Jiang S
Cancer Rep (Hoboken); 2023 Sep; 6(9):e1864. PubMed ID: 37501598
[TBL] [Abstract][Full Text] [Related]
22. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
23. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
[TBL] [Abstract][Full Text] [Related]
24. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
25. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
26. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
Wilks ST
Breast; 2015 Oct; 24(5):548-55. PubMed ID: 26187798
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
Morrow PK; Wulf GM; Ensor J; Booser DJ; Moore JA; Flores PR; Xiong Y; Zhang S; Krop IE; Winer EP; Kindelberger DW; Coviello J; Sahin AA; Nuñez R; Hortobagyi GN; Yu D; Esteva FJ
J Clin Oncol; 2011 Aug; 29(23):3126-32. PubMed ID: 21730275
[TBL] [Abstract][Full Text] [Related]
28. Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
Berns K; Sonnenblick A; Gennissen A; Brohée S; Hijmans EM; Evers B; Fumagalli D; Desmedt C; Loibl S; Denkert C; Neven P; Guo W; Zhang F; Knijnenburg TA; Bosse T; van der Heijden MS; Hindriksen S; Nijkamp W; Wessels LF; Joensuu H; Mills GB; Beijersbergen RL; Sotiriou C; Bernards R
Clin Cancer Res; 2016 Nov; 22(21):5238-5248. PubMed ID: 27172896
[TBL] [Abstract][Full Text] [Related]
29. CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.
Ji D; Luo Y; Wang J; Chen S; Lan B; Ma F; Xu B; Fan Y
BMC Cancer; 2023 Aug; 23(1):805. PubMed ID: 37644396
[TBL] [Abstract][Full Text] [Related]
30. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Heudel P; Frenel JS; Dalban C; Bazan F; Joly F; Arnaud A; Abdeddaim C; Chevalier-Place A; Augereau P; Pautier P; Chakiba C; You B; Lancry-Lecomte L; Garin G; Marcel V; Diaz JJ; Treilleux I; Pérol D; Fabbro M; Ray-Coquard I
JAMA Oncol; 2022 Jul; 8(7):1001-1009. PubMed ID: 35551299
[TBL] [Abstract][Full Text] [Related]
31. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Saura C; Bendell J; Jerusalem G; Su S; Ru Q; De Buck S; Mills D; Ruquet S; Bosch A; Urruticoechea A; Beck JT; Di Tomaso E; Sternberg DW; Massacesi C; Hirawat S; Dirix L; Baselga J
Clin Cancer Res; 2014 Apr; 20(7):1935-45. PubMed ID: 24470511
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Gayle SS; Arnold SL; O'Regan RM; Nahta R
Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
[TBL] [Abstract][Full Text] [Related]
33. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.
Wang J; Yu Y; Lin Q; Zhang J; Song C
J Cancer Res Clin Oncol; 2024 Jan; 150(1):21. PubMed ID: 38244085
[TBL] [Abstract][Full Text] [Related]
35. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
37. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway.
Qiu N; He YF; Zhang SM; Zhan YT; Han GD; Jiang M; He WX; Zhou J; Liang HL; Ao X; Xia HM; Li J; Yang YY; He ZM; Zou ZZ; Li HS
Cancer Lett; 2019 Nov; 464():25-36. PubMed ID: 31461670
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
39. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
Narayanankutty A
Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Emens LA; Esteva FJ; Beresford M; Saura C; De Laurentiis M; Kim SB; Im SA; Wang Y; Salgado R; Mani A; Shah J; Lambertini C; Liu H; de Haas SL; Patre M; Loi S
Lancet Oncol; 2020 Oct; 21(10):1283-1295. PubMed ID: 33002436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]